Navigation Links
Amgen Announces 2013 Second Quarter Dividend
Date:3/6/2013

our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... today declared a $0.61 per share dividend for the ... on Sept. 5, 2014, to all stockholders of record ... 2014.  About Amgen Amgen is committed ... from serious illnesses by discovering, developing, manufacturing and delivering ...
(Date:7/25/2014)... -- Trillions of bacteria live in each person,s digestive ... digest food and stave off harmful infections, but their ... To help shed light on the role of these ... professor Eric Alm recently tracked fluctuations in the bacterial ... The findings, described in the July 25 issue of ...
(Date:7/25/2014)... the University of Leicester has furthered our understanding ... to create new materials using nanosized ,building blocks,. ... the prestigious academic journal Physical Review Letters ... in rich detail the structure and internal atomic ... molecule and a single helium atom. , The ...
(Date:7/25/2014)... DUBLIN , July 25, 2014 ... of the "Global Metabolomics Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics ... metabolites. Metabolomics has become a new experimental technique ... and the environmental sciences. Metabolites are small molecules ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/,-- Evotec ... it has,successfully completed a Phase I safety and ... the good tolerability profile of EVT,302 and are ... EVT 302, a reversible and highly selective inhibitor ...
... SANTA MONICA, Calif., Jan. 7 Aida,Pharmaceuticals, Inc. ... received an award from the Science and Technology ... in China and known throughout,the country for its ... authority because of its "clinical research and,commercialization of ...
... from the department of macromolecular science and engineering ... Cleveland VA Medical Center and the NASA Glenn ... Nature Nanotechnology, one of the worlds most prestigious ... Jeffrey R. Capadona, associate investigator at the VAs ...
Cached Biology Technology:Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 2Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 3Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 4Phase I Safety and Tolerability Study With EVT 302 Successfully Completed 5Aida Receives Chinese Government Innovation Award 2
(Date:7/25/2014)... N.Y., July 25, 2014 In the first broad-scale estimate ... Service scientists and collaborators calculated that trees are saving ... 670,000 incidences of acute respiratory symptoms. , While trees, ... of less than 1 percent, the impacts of that ... of the reduced air pollution at nearly $7 billion ...
(Date:7/25/2014)... colonial era, 100,000s of people lived on the land ... fire to control the availability of plants they used ... to use fire to maintain desired habitat and natural ... Forest Service,s Pacific Southwest Station, will lead a ... Refuge during the Ecological Society of America,s 99th Annual ...
(Date:7/25/2014)... on this false-color image from the Terra satellite show the ... of wildfires in Eastern Russia. The burn scars show ... The wildfires have broken across the remote parts of ... false-color image from the MODIS instrument, it is still ... continue. Two recent image features noted below show the devastating ...
Breaking Biology News(10 mins):First national study finds trees saving lives, reducing respiratory problems 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... 2010 Country roadways can be hazardous for moose and ... elk and caribou in North America and Europe each year. ... pools that collect following pavement deicing. Because moose ... weighing up to 720 kilograms, their salt cravings can pose ...
... the Free State in South Africa (Ren Fourie and Charles ... (Rudy Jocqu) discovered very poorly known purse-web spiders of the ... new to science. The study was published in the open ... unique about purse-web spiders is that, in contrast to trapdoor ...
... have shown that a new experimental vaccine helps to ... from CSIRO,s Australian Animal Health Laboratory (AAHL) will announce ... Australian Veterinary Association conference in Adelaide today. "Our ... the infection of horses with Hendra virus," Dr Middleton ...
Cached Biology News:Of moose and men 2Vaccine protects from deadly Hendra virus 2
Form: Ready to use Applications: Immunohistology-frozen, Immunohistology-paraffin, Western Blot, ELISA...
... x W x H): 17 3/4" ... lbsCapacity: 12 slidesTime: Programmable 0 - 100 ... and hybridization steps 40 user programmable protocols ... Fixed temperature) Rapid temperature ramp-up from 37 ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Anti-Mouse Macrophages (Metallophillic), Purified (Clone MOMA-1) (rat IgG2a)...
Biology Products: